N-(4-fluorophenylsulfonyl)-D-valyl-L-leucinal

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(4-fluorophenylsulfonyl)-D-valyl-L-leucinal
• 英文别名: (2R)-2-[(4-fluorophenyl)sulfonylamino]-3-methyl-N-[(2S)-4-methyl-1-oxopentan-2-yl]butanamide
• 化学式: C₁₇H₂₅FN₂O₄S
• 分子量: 372.461
• InChiKey: WSJWUIDLGZAXID-GOEBONIOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  D-缬氨酸 在 sodium hydroxide 、 pyridine-SO3 complex 、 二甲基亚砜 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 24.67h， 生成 N-(4-fluorophenylsulfonyl)-D-valyl-L-leucinal
  参考文献：
  名称：

  Structure−Activity Relationship Study and Drug Profile of N-(4-Fluorophenylsulfonyl)-l-valyl-l-leucinal (SJA6017) as a Potent Calpain Inhibitor

  摘要：

  Novel N-arylsulfonyldipeptidyl aldehyde derivatives were prepared by DMSO oxidation from the corresponding dipeptide alcohol, and their potencies as calpain inhibitors were evaluated in vitro. Among them, N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (8, SJA6017) potently inhibited calpains. 8 also inhibited cathepsin B and L but did not inhibit other cysteine proteases (interleukin 1beta-converting enzyme), serine proteases (trypsin, chymotrypsin, thrombin, factor VIIa, factor Xa), or proteasome. Preliminary cytotoxicity studies of 8 exhibited a relatively safe profile.

  DOI：

  10.1021/jm0201924

文献信息

• OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEOUS ABSORPTION
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP1221315A1

  公开（公告）日：2002-07-10

  Ophthalmic transdermal patches are disclosed for treating diseases of the posterior segment of the eye comprising a drug-containing layer uniformly containing in a base matrix a percutaneous absorption enhancer, which is polyoxyethylene oleyl ether and/or isopropyl myristate, and a drug to be delivered to the posterior segment of the eye including the lens, the vitreous body, the uvea and the retina.

  本发明公开了用于治疗眼球后段疾病的眼科透皮贴片，该贴片包括一个含药层，在基质中均匀地含有一种经皮吸收促进剂，该促进剂是聚氧乙烯油基醚和/或肉豆蔻酸异丙酯，以及一种要输送到眼球后段（包括晶状体、玻璃体、葡萄膜和视网膜）的药物。
• DRUG COMPOSITION COMPRISING DIPEPTYDYL ALDEHYDE DERIVATIVE
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP1334718A1

  公开（公告）日：2003-08-13

  The present invention provides a preparation containing a compound of the formula (I) wherein R1 is an alkyl group having 1 to 4 carbon atoms or an optionally substituted aryl group having 6 to 10 carbon atoms; R2 and R3 are the same or different and each is hydrogen or an alkyl group having 1 to 4 carbon atoms, or R2 and R3 in combination form a ring having 3 to 7 carbon atoms; and R4 is a lower alkyl group optionally substituted by aryl, cycloalkyl or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof together with a lipid. The preparation shows improved stability and improved absorption and penetration into tissue.

  本发明提供了一种含有式（I）化合物的制剂 其中 R1 是具有 1 至 4 个碳原子的烷基或具有 6 至 10 个碳原子的任选取代的芳基；R2 和 R3 相同或不同，且各自是氢或具有 1 至 4 个碳原子的烷基，或 R2 和 R3 结合形成具有 3 至 7 个碳原子的环；R4 是任选被芳基、环烷基或芳香杂环残基取代的低级烷基，或其药学上可接受的盐以及脂质。该制剂显示出更高的稳定性，以及更好的吸收性和组织渗透性。
• Drug composition comprising dipeptidyl aldehyde derivative
  申请人：——

  公开号：US20040048929A1

  公开（公告）日：2004-03-11

  The present invention provides a preparation containing a compound of the formula (I) 1 wherein R 1 is an alkyl group having 1 to 4 carbon atoms or an optionally substituted aryl group having 6 to 10 carbon atoms; R 2 and R 3 are the same or different and each is hydrogen or an alkyl group having 1 to 4 carbon atoms, or R 2 and R 3 in combination form a ring having 3 to 7 carbon atoms; and R 4 is a lower alkyl group optionally substituted by aryl, cycloalkyl or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof together with a lipid. The preparation shows improved stability and improved absorption and penetration into tissue.

  本发明提供了一种含有式（I）化合物的制剂 1 其中 R 1 是具有 1 至 4 个碳原子的烷基或具有 6 至 10 个碳原子的任选取代的芳基；R 2 和 R 3 相同或不同，且各自为氢或具有 1 至 4 个碳原子的烷基，或 R 2 和 R 3 组合形成一个具有 3 至 7 个碳原子的环；以及 R 4 是可选被芳基、环烷基或芳香杂环残基取代的低级烷基，或其与脂质一起组成的药学上可接受的盐。该制剂具有更好的稳定性，更易被组织吸收和渗透。
• Angiogenesis inhibitor
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP0771565B1

  公开（公告）日：2003-01-02
• US6057290A
  申请人：——

  公开号：US6057290A

  公开（公告）日：2000-05-02